arrow
C

Chiara Catania

University of Brescia
H指数:13
被引数:779

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Transcriptional evidence of neuroendocrine cell plasticity beyond histological boundaries in lung neuroendocrine neoplasms: an in-silico analysis suggesting a progression model

肺神经内分泌新生物中超越组织学边界的神经内分泌细胞塑性的转录证据:一项提示进展模型的计算机分析

2026-07-280
OA
Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective

神经内分泌肺肿瘤分类的病理学、分子生物学、医学肿瘤学及放射治疗意义:多学科视角

2025-11-010
PRE
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group
2025-04-010
PRE
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

停用免疫检查点抑制剂的晚期实体瘤患者的结局: 系统回顾和荟萃分析

2024-07-010
OAAI
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group
2023-10-013
PRE
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study (vol 171, pg 183, 2022)
2023-05-010
OAAI
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
2022-08-0110
PRE
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial

手术切除的NSCLC患者强化临床和放射学随访的有效性。来自前瞻性MAGRIT试验的2661例患者分析

2020-01-019
PREAI